{
    "clinical_study": {
        "@rank": "121140", 
        "arm_group": [
            {
                "arm_group_label": "early ovarian cancer group"
            }, 
            {
                "arm_group_label": "locally advanced cervical cancer group"
            }, 
            {
                "arm_group_label": "primary endometrial cancer group"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to identify the incidence,feature,clinical significance for leg\n      lymphedema after gynecologic cancer treatment."
        }, 
        "brief_title": "Cross-sectional and Questionnaire Study for Leg Lymphedema", 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "condition": "Gynecologic Cancer", 
        "condition_browse": {
            "mesh_term": "Lymphedema"
        }, 
        "detailed_description": {
            "textblock": "Medical records will reviewed. And all patients who met the inclusion criteria will\n      contacted by a telephone call by a clinical research coordinator. The telephone interview\n      questionnaire for Lower Extremity Edema (LEE) and gynecologic cancer lymphedema\n      questionnaire (GCLQ) will t take approximately 20-30 min to complete. The questionnaire for\n      LEE included onset, severity, location, duration, and management. Patients will also\n      questioned concerning deep vein thrombosis  to exclude other causes of LEE. LEE is defined\n      as subjective edema of lower extremity based on patients' complaint. LLL is defined based on\n      a clinical diagnosis of lymphedema by a physician."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  Inclusion criteria\n\n               1. the patient who gynecologic cancer treatment at National Cancer Center ,\n                  Korea(2001~2011)\n\n               2. no active cancer treatment at the moment\n\n               3. available telephone communication\n\n          -  exclusion criteria 1. The patient unlikely to comply with the protocol\n\n        <More information by cancer type>\n\n          -  early ovarian cancer group Inclusion criteria were early stage epithelial ovarian\n             cancer*, no active treatment, available telephone communication with patients, and\n             ability and willingness to provide verbal informed consent.\n\n             *early ovarian cancer (FIGO stage I and II) at National Cancer Center, Korea who\n             underwent cytoreductive and staging surgery between January 2001 and December 2010\n\n          -  locally advanced cervical cancer group patients with locally advanced cervical cancer\n             who treatment at National Cancer Center, Korea between October 2001 and July 2007. Of\n             222 patients with locally advanced cervical cancer, 74  patients were underwent\n             pretreatment laparoscopic surgical staging and 148 patients received radiotherapy .\n             Women with locally advanced cervical cancer, no active treatment at survey, available\n             telephone communication, and ability and willingness to provide verbal informed\n             consent were considered to include in the current study.\n\n          -  primary endometrial cancer group patients with endometrial cancer who underwent\n             surgery, no active treatment at survey, available telephone communication, and\n             ability and willingness to provide verbal informed consent were considered to include\n             in the current study"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "the patient who gynecologic cancer treatment at National Cancer Center (2001~2011)"
            }
        }, 
        "enrollment": {
            "#text": "333", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02069171", 
            "org_study_id": "NCC_GO_2012_01_2", 
            "secondary_id": "NCCNCS-12-565"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Lower extremity edema", 
            "Lower leg lymphedema", 
            "Lower leg edema", 
            "Lymphedema", 
            "Pelvic lymph node dissection", 
            "Gynecologic Cancer Lymphedema Questionnaire"
        ], 
        "lastchanged_date": "February 19, 2014", 
        "number_of_groups": "3", 
        "official_title": "The Cross-sectional and Questionnaire Study of Pelvic and Lower Extremity Lymphedema After Treatment of Gynecological Disease", 
        "overall_official": {
            "affiliation": "National Cancer Center, Korea", 
            "last_name": "Myong Cheol Lim, MD,PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "There are no more follow up except one time telephone interview.", 
            "measure": "Gynecologic Cancer Lymphedema Questionnaire", 
            "safety_issue": "No", 
            "time_frame": "The study outcome measure will be assessed by telephone interview , one time."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02069171"
        }, 
        "responsible_party": {
            "investigator_affiliation": "National Cancer Center, Korea", 
            "investigator_full_name": "Myong Cheol Lim", 
            "investigator_title": "Faculty, Center for Uterine Cancer", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "National Cancer Center, Korea", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Center, Korea", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}